e-Health funding: Why the Q3 2025 slump is an opportunity for chronic disease management
From financial rationalisation to clinical efficiency: the new paradigm for chronic care.
€66 million. That is the historically low amount raised by French e-health start-ups in the third quarter of 2025. After a decade of euphoria driven by the "Startup Nation" momentum and the systemic boost of the COVID crisis, the market has corrected by 56% in one year. But make no mistake: this is not a rejection, it is a transformation. While investors are turning off the tap for peripheral services disconnected from care, they are concentrating their capital on medico-economic efficiency and clinical evidence. For chronic diseases — with oncology on the front line — this selectivity marks the end of fragmentation and the start of the era of high value-added solutions.
The e-health market: a phase of forced maturity
The latest Mind Health barometer leaves no room for doubt: with only €289.9M raised over the whole of 2025, French Tech Health is entering a new era. We are witnessing the end of the Growth at all costs dogma (raw growth in user numbers) in favour of the Path to Profitability.
This transition is not simple financial caution; it is a requirement for viability. In 2026, raising funds or convincing an industrial partner requires demonstrating the ability to fit into a sustainable business model. The segments still doing well, such as generative AI applied to diagnosis or large-scale use of clinical data, have one thing in common: they meet the immediate operational needs of hospitals and pharmaceutical companies under pressure.
The rejection of "Point Solutions": towards the end of fragmentation
One of the key lessons of this market correction is the growing lack of interest in Point Solutions. These isolated tools, which address only one micro-step of the care pathway without communicating with the rest of the ecosystem, have become a point of friction in the healthcare system. Oncologists, like specialists in cardiovascular disease or diabetes, now refuse to multiply interfaces.
The priority investment criterion has become medico-economic efficiency. A digital tool is no longer judged on its ergonomics, but on its systemic impact:
- Does it reduce the rate of unplanned emergency hospitalisations?
- Does it improve long-term treatment adherence?
- Does it help optimise medical time by filtering relevant alerts?
Chronic conditions, because of their complexity and duration, are the natural beneficiaries of this rationalisation. They require a level of coordination that only an integrated platform — able to bridge the patient's home and hospital expertise — can offer.
Jinko's strategic response: a coherent care architecture
In this rapidly changing landscape, Jinko's positioning illustrates what decision-makers expect from a technology partner in 2026. We no longer see ourselves as a simple app, but as an infrastructure for monitoring Quality of Life (QoL).
Our model rests on one conviction: the value of an e-health solution is measured by its clinical and industrial usefulness.
- For caregivers, Jinko is a tool that secures the care pathway by automating the reporting of critical data.
- For pharmaceutical companies, we become an engine for generating real-world evidence (RWE), essential for supporting the price of molecules with health authorities.
By turning the monitoring of well-being and side effects into structured, actionable data, we meet every point on the maturity "checklist" imposed by the market: proven clinical usefulness, seamless integration into the medical workflow and direct financial impact.
- Natural market selection: The fall in investment weeds out superficial tools, keeping only solutions able to prove their impact on public health.
- Well-being as a clinical lever: The market no longer funds well-being as an "optional extra", but as a pillar of therapeutic effectiveness (better Quality of Life means better treatment adherence).
- RWE as a safe haven: Real-world data is establishing itself as the most strategic asset to sustain start-ups' business models and industry's Market Access.
Sources:
- EY venture capital barometer in France - 2025 annual review
- EY venture capital barometer in France - Q3 2025
- Barometer of the economic and social performance of French start-ups and venture capital funds
- France Healthtech Panorama 2024
- G_NIUS - Health Innovation Portal
- Bpifrance - Innovation Capital Observatory
- French e-health start-ups raised €66 million in Q3 2025
Satisfied patients and doctors
“Jinko is my new haven of peace.
The kindness, the listening, the care, the follow-up, the practitioners… The nurses are very attentive, always ready to help, to improve the follow-up and adapt it. Jinko helps me every day: I have been able to take up (adapted) physical activity again and take back control of my body.
Thank you to the whole team who welcomed me into the care pathway.”
“Jinko is a precious, essential and beneficial resource for anyone living with cancer or in remission. The care pathway offered is tailored to my needs, I discovered new therapies, and the network of selected practitioners is of very high quality: attentive, empathetic, supportive, caring… Thank you to the whole Jinko team for your commitment, your support, your humanity and the strength you give us!”
“Jinko was a precious support for me during my cancer treatment, filling the gaps that often exist in medical follow-up. The team stands out for its empathy, compassion and commitment to supporting patients in every aspect of their lives, during and after treatment. Thank you to Sophie and the whole team for their exceptional humanity and unmatched availability.”
“Jinko works hard to understand patients’ needs as closely as possible and knows how to support them at the right time, in the right way. Doctors need people to take over from them, and it is a very good thing that Jinko has taken this initiative.”
